TurnerBESteinbergJRWeeksBT, et al. Race/ethnicity reporting and representation in US clinical trials: A cohort study. Lancet Reg Health Am2022; 11: 100252.
3.
HittleMCulpepperWJLanger-GouldA, et al. Population-based estimates for the prevalence of multiple sclerosis in the United States by race, ethnicity, age, sex, and geographic region. JAMA Neurol2023; 80: 693–701.
4.
OnuorahHMCharronOMeltzerE, et al. Enrollment of non-white participants and reporting of race and ethnicity in phase III trials of multiple sclerosis DMTs: A systematic review. Neurology2022; 98: e880–e892.
5.
FDA takes important steps to increase racial and ethnic diversity in clinical trials. Silver Spring, MD: US Food and Drug Administration (FDA), 2022.
6.
SimonsRLLeiMKKlopackE, et al. Racial discrimination, inflammation, and chronic illness among African American women at midlife: Support for the weathering perspective. J Racial Ethn Health Disparities2021; 8: 339–349.
7.
ConwayDSBriggsFBMowryEM, et al. Racial disparities in hypertension management among multiple sclerosis patients. Mult Scler Relat Disord2022; 64: 103972.
8.
FinlaysonMAl-MashitaLSandhuR. Participant diversity in clinical trials of rehabilitation interventions for people with multiple sclerosis: A scoping review. Mult Scler2023; 29: 1149–1157.
9.
SaadiAHimmelsteinDUWoolhandlerS, et al. Racial disparities in neurologic health care access and utilization in the United States. Neurology2017; 88: 2268–2275.
10.
ReopellLNolanTSGrayDM, et al. Community engagement and clinical trial diversity: Navigating barriers and co-designing solutions-A report from the “Health Equity through Diversity” seminar series. PLoS One2023; 18: e0281940.
11.
Pimentel MaldonadoDAMorenoAWilliamsMJ, et al. Perceptions and preferences regarding multiple sclerosis research among racial and ethnic groups. Int J MS Care2021; 23: 170–177.
WilliamsMJOkaiAFCrossAH, et al. Demographics and baseline disease characteristics of Black and Hispanic patients with multiple sclerosis in the open-label, single-arm, multicenter, phase IV CHIMES trial. Mult Scler Relat Disord2023; 76: 104794.
14.
JettyAHyppoliteJEdenAR, et al. Underrepresented minority family physicians more likely to care for vulnerable populations. J Am Board Fam Med2022; 35: 223–224.
15.
OvbiageleBAmezcuaLCruz-FloresSC, et al. Health disparities research curricula and training development: Recommendations from a National Institute of Neurological Disorders and Stroke workgroup. Neurology2023; 101: S47–S58.
16.
GomezLEBernetP. Diversity improves performance and outcomes. J Natl Med Assoc2019; 111: 383–392.
17.
MariottoSBeatriceGCartaS, et al. Gender disparity in editorial boards of journals in neurology. Neurology2020; 95: 489–491.
18.
SinghalDBankAMPoormanJA, et al. Representation of women plenary speakers at the American Academy of Neurology Annual Meeting. Neurology2020; 95: e3045–e3059.
19.
RossLHassettCBrownP, et al. Gender representation among physician authors of practice guidelines developed, endorsed, or affirmed by the American Academy of Neurology. Neurology2023; 100: e465–e472.
20.
HallDACahillCMeyerAL, et al. Gender disparities in the career of neurology researchers. Neurology2023; 100: e454–e464.
21.
ThomsonAHorneRChungC, et al. Visibility and representation of women in multiple sclerosis research. Neurology2019; 92: 713–719.
